Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17379

Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka

{"title":"Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.","authors":"Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka","doi":"10.21873/anticanres.17379","DOIUrl":null,"url":null,"abstract":"Background/aim: Few studies have examined the association between programmed cell death ligand 1 (PD-L1) expression in small cell lung cancer and the effect of chemoimmunotherapy.Patients and methods: Patients diagnosed with extensive-stage small cell lung cancer at our hospital between September 2019 and August 2023, who were treated with atezolizumab plus carboplatin and etoposide and had pathological tissue immunostained with SP142, were retrospectively examined to determine whether treatment efficacy differed depending on the expression of PD-L1.Results: Twenty-nine patients were analyzed. SP142 immunostaining revealed that the tumor cell (TC) score was 3, 2, 1, and 0 in 1, 0, 0, and 28 cases, respectively. The tumor-infiltrating cell (IC) score was 3, 2, 1, and 0 in 1, 0, 5, and 23 cases, respectively. The median progression-free survival (PFS) of the patients who tested positive and negative for TC was 13 and 5 months, respectively [hazard ratio (HR)=0.041; 95% confidence interval (CI)=0.000-36.225; p=0.109]; and the median overall survival (OS) was 13 and 7.5 months (HR=0.046; 95%CI=0.000-948.833; p=0.338), respectively. The median PFS of the patients who tested positive and negative for IC was 8 and 4 months, respectively (HR=0.216; 95%CI=0.061-0.765; p=0.004); the median OS was 15 and 8 months, respectively (HR=0.573; 95%CI=0.168-1.955; p=0.346).Conclusion: Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5531-5539"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Few studies have examined the association between programmed cell death ligand 1 (PD-L1) expression in small cell lung cancer and the effect of chemoimmunotherapy.

Patients and methods: Patients diagnosed with extensive-stage small cell lung cancer at our hospital between September 2019 and August 2023, who were treated with atezolizumab plus carboplatin and etoposide and had pathological tissue immunostained with SP142, were retrospectively examined to determine whether treatment efficacy differed depending on the expression of PD-L1.

Results: Twenty-nine patients were analyzed. SP142 immunostaining revealed that the tumor cell (TC) score was 3, 2, 1, and 0 in 1, 0, 0, and 28 cases, respectively. The tumor-infiltrating cell (IC) score was 3, 2, 1, and 0 in 1, 0, 5, and 23 cases, respectively. The median progression-free survival (PFS) of the patients who tested positive and negative for TC was 13 and 5 months, respectively [hazard ratio (HR)=0.041; 95% confidence interval (CI)=0.000-36.225; p=0.109]; and the median overall survival (OS) was 13 and 7.5 months (HR=0.046; 95%CI=0.000-948.833; p=0.338), respectively. The median PFS of the patients who tested positive and negative for IC was 8 and 4 months, respectively (HR=0.216; 95%CI=0.061-0.765; p=0.004); the median OS was 15 and 8 months, respectively (HR=0.573; 95%CI=0.168-1.955; p=0.346).

Conclusion: Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.

查看原文本刊更多论文

广泛期小细胞肺癌中PD-L1表达与化学免疫治疗疗效的关系

背景/目的：很少有研究探讨小细胞肺癌中程序性细胞死亡配体1 （PD-L1）表达与化学免疫治疗效果之间的关系。患者和方法：回顾性检查2019年9月至2023年8月在我院诊断为广泛期小细胞肺癌的患者，这些患者接受阿特唑单抗联合卡铂和依托泊苷治疗，并进行病理组织SP142免疫染色，以确定治疗效果是否取决于PD-L1的表达。结果：分析29例患者。SP142免疫染色显示肿瘤细胞（TC）评分分别为3、2、1、0，分别为1、0、0、28例。肿瘤浸润细胞（IC）评分分别为3、2、1、0，分别为1、0、5、23例。TC阳性和阴性患者的中位无进展生存期（PFS）分别为13个月和5个月[风险比(HR)=0.041；95%置信区间(CI)=0.000-36.225；p = 0.109);中位总生存期（OS）分别为13和7.5个月(HR=0.046；95%可信区间= 0.000 - -948.833;分别p = 0.338)。IC阳性和阴性患者的中位PFS分别为8个月和4个月(HR=0.216；95%可信区间= 0.061 - -0.765;p = 0.004);中位生存期分别为15个月和8个月(HR=0.573；95%可信区间= 0.168 - -1.955;p = 0.346)。结论：IC阳性患者的PFS明显长于阴性患者。因此，PD-L1表达可能是广泛期小细胞肺癌化疗免疫治疗疗效的预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.